

**Anti-ELOVL1 Antibody (Internal)**  
**Rabbit Anti Human Polyclonal Antibody**  
**Catalog # ALS18448****Specification**

---

**Anti-ELOVL1 Antibody (Internal) - Product Information**

|                   |                           |
|-------------------|---------------------------|
| Application       | WB, IHC-P                 |
| Primary Accession | <a href="#">Q9BW60</a>    |
| Predicted         | Human, Mouse, Rat, Monkey |
| Host              | Rabbit                    |
| Clonality         | Polyclonal                |
| Calculated MW     | 32663                     |
| Dilution          | WB~~1:1000<br>IHC-P~~N/A  |

**Anti-ELOVL1 Antibody (Internal) - Additional Information****Gene ID** 64834**Alias Symbol** **ELOVL1****Other Names**

ELOVL1, ELOVL FA elongase 1, ELOVL fatty acid elongase 1, Ssc1, CGI-88

**Target/Specificity**

Recognizes endogenous levels of ELOVL1 protein.

**Reconstitution & Storage**

Immunoaffinity purified

**Precautions**

Anti-ELOVL1 Antibody (Internal) is for research use only and not for use in diagnostic or therapeutic procedures.

**Anti-ELOVL1 Antibody (Internal) - Protein Information****Name** ELOVL1 ([HGNC:14418](#))**Synonyms** SSC1**Function**

Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle (PubMed:<a href="http://www.uniprot.org/citations/29496980" target="\_blank">29496980</a>, PubMed:<a href="http://www.uniprot.org/citations/30487246" target="\_blank">30487246</a>). This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and monounsaturated acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in

multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis (PubMed:<a href="http://www.uniprot.org/citations/20937905" target="\_blank">20937905</a>). Indirectly inhibits RPE65 via production of VLCFAs.

**Cellular Location**

Endoplasmic reticulum membrane {ECO:0000255|HAMAP-Rule:MF\_03201, ECO:0000269|PubMed:20937905, ECO:0000269|PubMed:30487246}; Multi-pass membrane protein {ECO:0000255|HAMAP-Rule:MF\_03201}

**Tissue Location**

Ubiquitous.

**Anti-ELOVL1 Antibody (Internal) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-ELOVL1 Antibody (Internal) - Images**